Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Evolocumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 14Repatha

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Repatha

    Evolocumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Repatha

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Amgen

    Evolocumab

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2020 Revenue in Millions : 887

    2019 Revenue in Millions : 661

    Growth (%) : 34

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Repatha

    Evolocumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Repatha

    Japan
    arrow
    Antibody Engineering
    Not Confirmed

    Astellas

    Evolocumab

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2020 Revenue in Millions : 43

    2019 Revenue in Millions : 27

    Growth (%) : 57

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Repatha

    Evolocumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Repatha

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Amgen

    Evolocumab

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2021 Revenue in Millions : 1,117

    2020 Revenue in Millions : 887

    Growth (%) : 26

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Repatha

    Evolocumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Repatha

    Japan
    arrow
    Antibody Engineering
    Not Confirmed

    Astellas

    Evolocumab

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2021 Revenue in Millions : 48

    2020 Revenue in Millions : 43

    Growth (%) : 21

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Repatha

    Evolocumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Repatha

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Amgen

    Evolocumab

    Main Therapeutic Indication : Cardiology/Vascular Diseases

    Currency : USD

    2022 Revenue in Millions : 1,296

    2021 Revenue in Millions : 1,117

    Growth (%) : 16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Repatha

    Evolocumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Repatha

    Japan
    arrow
    Antibody Engineering
    Not Confirmed

    Astellas

    Evolocumab

    Main Therapeutic Indication : Cardiology/Vascular Diseases

    Currency : USD

    2022 Revenue in Millions : 47

    2021 Revenue in Millions : 49

    Growth (%) : -4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Repatha

    Evolocumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Repatha

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Amgen

    Evolocumab

    Main Therapeutic Indication : Cardiology/Vascular Diseases

    Currency : USD

    2023 Revenue in Millions : 1,635

    2022 Revenue in Millions : 1,296

    Growth (%) : 26

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Repatha

    Evolocumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Repatha

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Amgen

    Evolocumab

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2017 Revenue in Millions : 319

    2016 Revenue in Millions : 141

    Growth (%) : 126

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Repatha

    Evolocumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Repatha

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Amgen

    Evolocumab

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2018 Revenue in Millions : 550

    2017 Revenue in Millions : 319

    Growth (%) : 72%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Repatha

    Evolocumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Repatha

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Amgen

    Evolocumab

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2016 Revenue in Millions : 141

    2015 Revenue in Millions : 10

    Growth (%) : 1,310

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF